186 Chapter 7 186. Te Rijdt, W. P. et al. Phospholamban p.Arg14del cardiomyopathy is characterized by phospholamban aggregates, aggresomes, and autophagic degradation. Histopathology 69, 542–550 (2016). 187. Sepehrkhouy, S. et al. Distinct fibrosis pattern in desmosomal and phospholamban mutation carriers in hereditary cardiomyopathies. Heart Rhythm 14, 1024–1032 (2017). 188. Te Rijdt, W. P. et al. Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging. Eur. Heart J. Cardiovasc. Imaging 20, 92–100 (2019). 189. Te Rijdt, W. P. et al. Distinct molecular signature of phospholamban p.Arg14del arrhythmogenic cardiomyopathy. Cardiovasc. Pathol. 40, 2–6 (2019). 190. Sepehrkhouy, S. et al. Distinct fibrosis pattern in desmosomal and phospholamban mutation carriers in hereditary cardiomyopathies. Heart Rhythm 14, 1024–1032 (2017). 191. Maione, A. S. et al. Fibrosis in Arrhythmogenic Cardiomyopathy: The Phantom Thread in the Fibro-Adipose Tissue. Front. Physiol. 11, (2020). 192. Mandawat, A. et al. Progression of Myocardial Fibrosis in Nonischemic DCM and Association With Mortality and Heart Failure Outcomes. JACC Cardiovasc. Imaging 14, 1338–1350 (2021). 193. Te Rijdt, W. P. et al. Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging. Eur. Heart J. Cardiovasc. Imaging 20, 92–100 (2019). 194. Te Rijdt, W. P. et al. Phospholamban p.Arg14del cardiomyopathy is characterized by phospholamban aggregates, aggresomes, and autophagic degradation. Histopathology 69, 542–550 (2016). 195. Liang, C., Wang, K., Li, Q., Bai, J. & Zhang, H. Influence of the distribution of fibrosis within an area of myocardial infarction on wave propagation in ventricular tissue. Sci. Rep. 9, 1–14 (2019). 196. Kazbanov, I. V., ten Tusscher, K. H. W. J. & Panfilov, A. V. Effects of Heterogeneous Diffuse Fibrosis on Arrhythmia Dynamics and Mechanism. Sci. Rep. 6, 20835 (2016). 197. van der Voorn, S. M. et al. Exploring the Correlation Between Fibrosis Biomarkers and Clinical Disease Severity in PLN p.Arg14del Patients. Front Cardiovasc Med 8, 802998 (2021). 198. Torre-Amione, G. Immune activation in chronic heart failure. Am. J. Cardiol. 95, (2005). 199. Asatryan, B. et al. Inflammation and Immune Response in Arrhythmogenic Cardiomyopathy: State-of-the-Art Review. Circulation 144, 1646–1655 (2021). 200. Eijgenraam, T. R. et al. Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)-Related Cardiomyopathy: Development of PLN-R14del-Related Cardiomyopathy. Circ. Heart Fail. 14, e008532 (2021). 201. Kamel, S. M. et al. Istaroxime treatment ameliorates calcium dysregulation in a zebrafish model of phospholamban R14del cardiomyopathy. Nat. Commun. 12, 7151 (2021). 202. Ponikowski, P. et al. [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. Kardiol. Pol. 74, 1037–1147 (2016). 203. Priori, S. G. et al. [2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac Death. The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology]. G. Ital. Cardiol. 17, 108–170 (2016). 204. Eijgenraam, T. R. et al. The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy. Sci. Rep. 10, 9819 (2020). 205. Eijgenraam, T. R. et al. The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy. Sci. Rep. 10, 9819 (2020). 206. van der Zwaag, P. A. et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur. J. Heart Fail. 14, 1199–1207 (2012). 207. Vaidya, Y., Riaz, S. & Dhamoon, A. S. Left Ventricular Assist Devices. in StatPearls (StatPearls Publishing, 2021). 208. Dubbel Dutch. https://dubbeldutchdenver.com/pln-letter-to-inform-community-in-north-america.
RkJQdWJsaXNoZXIy MTk4NDMw